Concord Biotech Ltd.
CONCORDBIOHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
12 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 12 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20230913 | 2023-06-30 | yes | |
| TRANSCRIPT | 20231116 | 2023-09-30 | yes | |
| TRANSCRIPT | 20240216 | 2023-12-31 | yes | |
| TRANSCRIPT | 20240604 | 2024-03-31 | yes | |
| TRANSCRIPT | 20240820 | 2024-06-30 | yes | |
| TRANSCRIPT | 20241119 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250221 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250818 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251119 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260218 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260605 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260807 | 2026-06-30 | yes |
CONCORDBIO
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 1,478.80 |
| 52-week range | 1014.8 – 1647.7 |
| Return 1M | -4.47% |
| Return 3M | 14.98% |
| Return 1Y | -9.25% |
| Return 3Y | 49.02% |
| Return 5Y | not reported for this period |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 257.00 |
| Other income | 13.00 |
| Total income | 270.00 |
| Cost of materials consumed | 70.00 |
| Purchases of stock-in-trade | 11.00 |
| Changes in inventories | -27.00 |
| Employee benefit expense | 44.00 |
| Finance costs | 0.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.44 | 0.00 |
| institutions foreign | 0.08 | -0.00 |
| institutions domestic | 0.09 | 0.00 |
| mutual funds | 0.04 | 0.00 |
| public | 0.56 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| TRANSCRIPT | 2026-06-30 | 12 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 195.00 | 262.00 | 241.00 | 319.00 | 216.00 | 310.00 | 244.00 | 430.00 | 204.00 | 247.00 | 278.00 | 326.00 | 257.00 |
| Other income | 7.00 | 8.00 | 8.00 | 11.00 | 10.00 | 10.00 | 15.00 | 9.00 | 14.00 | 13.00 | 10.00 | 15.00 | 13.00 |
| Total income | 201.00 | 270.00 | 249.00 | 330.00 | 226.00 | 320.00 | 259.00 | 439.00 | 218.00 | 260.00 | 288.00 | 341.00 | 270.00 |
| Cost of materials consumed | 39.00 | 42.00 | 47.00 | 56.00 | 55.00 | 68.00 | 61.00 | 80.00 | 60.00 | 57.00 | 67.00 | 71.00 | 70.00 |
| Purchases of stock-in-trade | 12.00 | 10.00 | 23.00 | 11.00 | 12.00 | 22.00 | 12.00 | 10.00 | 13.00 | 14.00 | 20.00 | 16.00 | 11.00 |
| Changes in inventories | -11.00 | 0.00 | -24.00 | 22.00 | -19.00 | -13.00 | -21.00 | 38.00 | -28.00 | -22.00 | -21.00 | -0.00 | -27.00 |
| Employee benefit expense | 28.00 | 30.00 | 31.00 | 34.00 | 32.00 | 34.00 | 35.00 | 39.00 | 38.00 | 44.00 | 47.00 | 48.00 | 44.00 |
| Finance costs | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation and amortisation | 13.00 | 13.00 | 14.00 | 14.00 | 13.00 | 13.00 | 13.00 | 15.00 | 18.00 | 18.00 | 19.00 | 20.00 | 18.00 |
| Other expenses | 54.00 | 60.00 | 57.00 | 62.00 | 55.00 | 64.00 | 59.00 | 72.00 | 60.00 | 65.00 | 66.00 | 74.00 | 77.00 |
| Total expenses | 136.00 | 157.00 | 149.00 | 199.00 | 148.00 | 187.00 | 160.00 | 254.00 | 160.00 | 177.00 | 198.00 | 227.00 | 193.00 |
| Profit before exceptional items and tax | 65.00 | 113.00 | 100.00 | 131.00 | 78.00 | 133.00 | 99.00 | 185.00 | 57.00 | 83.00 | 90.00 | 114.00 | 77.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.00 | 0.00 | 0.00 |
| Profit before tax | 65.00 | 113.00 | 100.00 | 131.00 | 78.00 | 133.00 | 99.00 | 185.00 | 57.00 | 83.00 | 87.00 | 114.00 | 77.00 |
| Current tax | 16.00 | 28.00 | 26.00 | 30.00 | 19.00 | 34.00 | 24.00 | 42.00 | 14.00 | 22.00 | 22.00 | 29.00 | 20.00 |
| Deferred tax | 0.00 | 1.00 | -0.00 | 4.00 | 1.00 | 1.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | -3.00 | 0.00 |
| Tax expense | 17.00 | 29.00 | 26.00 | 34.00 | 20.00 | 35.00 | 25.00 | 43.00 | 15.00 | 23.00 | 23.00 | 26.00 | 21.00 |
| Profit for the period | 54.00 | 81.00 | 78.00 | 95.00 | 60.00 | 96.00 | 76.00 | 140.00 | 44.00 | 63.00 | 64.00 | 88.00 | 58.00 |
| Profit attributable to owners | 54.00 | 81.00 | 78.00 | 95.00 | 60.00 | 0.00 | 76.00 | 140.00 | 44.00 | 64.00 | 64.00 | 89.00 | 59.00 |
| Profit attributable to non-controlling interests | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.00 | -1.00 | -0.00 | -1.00 |
| Other comprehensive income | -0.00 | 0.00 | -1.00 | 0.00 | 0.00 | -0.00 | -1.00 | 7.00 | -3.00 | 22.00 | 23.00 | 13.00 | 17.00 |
| Total comprehensive income | 54.00 | 81.00 | 77.00 | 95.00 | 60.00 | 96.00 | 74.00 | 148.00 | 41.00 | 85.00 | 87.00 | 102.00 | 75.00 |
| Earnings per share, basic | 5.21 | 7.74 | 7.41 | 9.08 | 5.70 | 9.15 | 7.26 | 13.42 | 4.21 | 6.03 | 6.08 | 8.46 | 5.52 |
| Earnings per share, diluted | 5.21 | 7.74 | 7.41 | 9.08 | 5.70 | 9.15 | 7.26 | 13.42 | 4.21 | 6.03 | 6.08 | 8.46 | 5.52 |
Annual results, as filed
| Line | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|
| Revenue from operations | 1,017.00 | 1,200.00 | 1,055.00 |
| Other income | 34.00 | 44.00 | 52.00 |
| Total income | 1,051.00 | 1,245.00 | 1,107.00 |
| Cost of materials consumed | 185.00 | 264.00 | 254.00 |
| Purchases of stock-in-trade | 57.00 | 56.00 | 63.00 |
| Changes in inventories | -12.00 | -15.00 | -71.00 |
| Employee benefit expense | 123.00 | 139.00 | 177.00 |
| Finance costs | 3.00 | 1.00 | 0.00 |
| Depreciation and amortisation | 54.00 | 54.00 | 74.00 |
| Other expenses | 233.00 | 249.00 | 265.00 |
| Total expenses | 642.00 | 749.00 | 762.00 |
| Profit before exceptional items and tax | 409.00 | 496.00 | 345.00 |
| Exceptional items | 0.00 | 0.00 | -3.00 |
| Profit before tax | 409.00 | 496.00 | 342.00 |
| Current tax | 100.00 | 119.00 | 86.00 |
| Deferred tax | 5.00 | 4.00 | -1.00 |
| Tax expense | 104.00 | 123.00 | 85.00 |
| Profit for the period | 308.00 | 372.00 | 259.00 |
| Profit attributable to owners | 308.00 | 372.00 | 261.00 |
| Profit attributable to non-controlling interests | — | 0.00 | -2.00 |
| Other comprehensive income | -0.00 | 6.00 | 55.00 |
| Total comprehensive income | 308.00 | 378.00 | 314.00 |
| Earnings per share, basic | 29.45 | 35.52 | 24.78 |
| Earnings per share, diluted | 29.45 | 35.52 | 24.78 |
Balance sheet, as filed
| Line | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|
| Total assets | 1,551.00 | 1,701.00 | 1,764.00 | 2,034.00 | 2,023.00 | 2,235.00 |
| Non-current assets | 795.00 | 804.00 | 830.00 | 899.00 | 943.00 | 985.00 |
| Current assets | 756.00 | 896.00 | 935.00 | 1,135.00 | 1,080.00 | 1,250.00 |
| Property, plant and equipment | 586.00 | 572.00 | 554.00 | 792.00 | 787.00 | 786.00 |
| Capital work-in-progress | 188.00 | 211.00 | 249.00 | 50.00 | 74.00 | 78.00 |
| Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other intangible assets | 1.00 | 4.00 | 4.00 | 2.00 | 2.00 | 2.00 |
| Inventories | 220.00 | 208.00 | 250.00 | 240.00 | 276.00 | 326.00 |
| Trade receivables | 267.00 | 350.00 | 344.00 | 522.00 | 397.00 | 460.00 |
| Cash and cash equivalents | 6.00 | 15.00 | 7.00 | 1.00 | 17.00 | 12.00 |
| Total equity and liabilities | 1,551.00 | 1,701.00 | 1,764.00 | 2,034.00 | 2,023.00 | 2,235.00 |
| Equity | 1,354.00 | 1,527.00 | 1,590.00 | 1,813.00 | 1,827.00 | 2,015.00 |
| Equity share capital | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Other equity | 1,344.00 | 1,516.00 | 1,580.00 | 1,802.00 | 1,817.00 | 2,007.00 |
| Total liabilities | 197.00 | 174.00 | 174.00 | 222.00 | 196.00 | 220.00 |
| Non-current liabilities | 29.00 | 32.00 | 32.00 | 37.00 | 41.00 | 51.00 |
| Current liabilities | 167.00 | 142.00 | 142.00 | 184.00 | 155.00 | 169.00 |
| Borrowings, non-current | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Borrowings, current | 19.00 | 6.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Trade payables | 76.00 | 94.00 | 82.00 | 113.00 | 87.00 | 102.00 |
Cash flow, as filed
| Line | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|
| Net cash from operating activities | 117.00 | 265.00 | 151.00 | 245.00 | 151.00 | 267.00 |
| Net cash from investing activities | -29.00 | -155.00 | -60.00 | -160.00 | -21.00 | -143.00 |
| Net cash from financing activities | -86.00 | -99.00 | -99.00 | -99.00 | -113.00 | -113.00 |
| Purchase of property, plant and equipment | 30.00 | 86.00 | 50.00 | 111.00 | 53.00 | 95.00 |
| Net increase in cash | 3.00 | 12.00 | -8.00 | -14.00 | 16.00 | 11.00 |
| con:CFO.BEFORE_TAX | 148.00 | 370.00 | 209.00 | 354.00 | 213.00 | 367.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 31.00 | 103.00 | 57.00 | 109.00 | 62.00 | 100.00 |
| con:CF_OTHER.OPERATING | 0.00 | -1.00 | 0.00 | -0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 838.00 | 534.00 | 870.00 | 461.00 | 947.00 |
| con:INVESTMENTS_SOLD | 0.00 | 746.00 | 513.00 | 801.00 | 478.00 | 882.00 |
| con:PPE_DISPOSALS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 44.08 | 44.08 | 44.08 | 44.08 | 44.08 | 44.08 | 44.08 | 44.08 | 0.44 | 0.44 | 0.44 | 0.44 |
| Domestic institutions | 8.18 | 8.46 | 8.46 | 10.40 | 9.89 | 9.66 | 9.16 | 8.87 | 0.10 | 0.10 | 0.09 | 0.09 |
| Mutual funds | — | — | — | — | — | — | — | 4.68 | 0.05 | 0.04 | 0.04 | 0.04 |
| Insurance companies | 2.26 | 2.47 | 2.88 | 4.53 | 4.30 | 4.18 | 3.35 | 3.41 | 0.04 | 0.04 | 0.04 | 0.04 |
| Foreign institutions | 7.30 | 7.00 | 6.48 | 7.11 | 8.10 | 8.33 | 9.35 | 9.11 | 0.08 | 0.08 | 0.08 | 0.08 |
| Public | 55.92 | 55.92 | 55.92 | 55.92 | 55.92 | 55.92 | 55.92 | 55.92 | 0.56 | 0.56 | 0.56 | 0.56 |
| Non-institutional | 40.44 | 40.46 | 40.97 | 38.41 | 37.93 | 37.93 | 37.41 | 37.95 | 0.38 | 0.39 | 0.39 | 0.39 |
| Shares outstanding | 104616204 | 104616204 | 104616204 | 104616204 | 104616204 | 104616204 | 104616204 | 104616204 | 104616204 | 104616204 | 104616204 | 104616204 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Sudhir Vaid | Key Management Personnel | Any other transaction, Dividend paid, Remuneration | 302,294,000.00 | 3 |
| Concord Biotech Japan K.K | Joint Venture | Sale of goods or services | 140,625,000.00 | 1 |
| Manju Vaid | Relatives of Key Management Person | Any other transaction, Dividend paid | 89,623,000.00 | 2 |
| Sudman Consultants LLP | Enterprises controlled by / under | Dividend paid | 41,580,000.00 | 1 |
| Ankur Vaid | Key Management Personnel | Dividend paid, Remuneration | 21,966,000.00 | 2 |
| Megha Vaid | Relatives of Key Management Person | Dividend paid, Remuneration | 8,624,000.00 | 2 |
| Sonal Kumra | Relatives of Key Management Person | Dividend paid, Remuneration | 4,887,000.00 | 2 |
| Lalit Sethi | Key Management Personnel | Remuneration | 2,993,000.00 | 1 |
| Col S. K Vaid | Relatives of Key Management Person | Any other transaction | 2,771,000.00 | 1 |
| Prakash Sajnani | Key Management Personnel | Dividend paid, Remuneration | 2,410,000.00 | 2 |
| Ravi Kapoor | Key Management Personnel | Any other transaction, Dividend paid | 1,968,000.00 | 2 |
| Ravi Kapoor & Associates | Enterprises controlled by / under | Any other transaction | 1,375,000.00 | 1 |
| Rajiv Ambrish Agarwal | Key Management Personnel | Dividend paid | 1,142,000.00 | 1 |
| Jayaram Easwaran | Key Management Personnel | Any other transaction | 160,000.00 | 1 |
| Arvind Agarwal | Key Management Personnel | Any other transaction, Dividend paid | 155,000.00 | 2 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-08-07 | Q1FY27 | LIMITED | Read the call |
| 2026-06-05 | FYFY26 | Read the call | |
| 2026-02-18 | FYFY26 | LIMITED | Read the call |
| 2025-11-19 | Q2FY26 | Read the call | |
| 2025-08-18 | Q1FY26 | Read the call | |
| 2025-02-21 | Read the call | ||
| 2024-11-19 | Q2FY25 | BIOTECH LIMITED | Read the call |
| 2024-08-20 | Q1FY25 | Biotecf for Mankind..., iotech for Mankind... | Read the call |
| 2024-06-04 | FYFY24 | BIOTECH LIMITED | Read the call |
| 2024-02-16 | Q3FY24 | CONCORD BIOTECH LIMITED | Read the call |
| 2023-11-16 | Q2FY24 | BIOTECH LIMITED | Read the call |
| 2023-09-13 | Q1FY24 | BIOTECH LIMITED | Read the call |
What they said about it, quarter by quarter
| Topic | Q1FY24 | Q1FY25 | Q1FY26 | Q1FY27 | Q2FY24 | Q2FY25 | Q2FY26 | Q3FY24 |
|---|---|---|---|---|---|---|---|---|
| Capex | But sir, in terms of any number that we look at asset return from the capex, I was close to INR 400 crores, INR 450 crores, something like that, capex… | — | — | Lastly, we are a zero debt company and with cash and cash equivalent of more than INR442 crores as on 30th June, our capex for the quarter stood at ar… | — | And regarding the capex, is it maintenance only or you plan to add more? | — | — |
| Capital allocation | — | By balancing prudent reinvestment with consistent dividend payouts, we aim to enhance overall shareholder value while maintaining a sustainable busine… | Secondly, in terms of the new acquisition that we have done on the US front. | — | — | — | — | — |
| Costs | With respect to any other risk, I won't call it a risk, but of course, any changes in the macroeconomic conditions could impact companies in the pharm… | — | — | However, when we see that we also have an impact of the input cost on certain aspects. | — | — | Not only for Valthera, but also for Dholka, because it can also be manufacturing certain raw materials, certain intermediates, which may be, say, now … | Most of our raw material procurement happens from within India, but if there are a few items that are imported, we have to closely monitor the situati… |
| Debt and cash | Our net debt as on 30th of June is stood at around INR 25 crores. | — | — | We have been consistently reporting positive operating cash flow. | — | Because what we understand is in the hospital business, probably the working capitals is a little elongated so and there are very less margins in the … | — | — |
| Demand | The API consumption for domestic formulations is also expected to drive high demand in the next four to five years. | Currently, we have a robust pipeline consisting of 8 to 10 new products which we plan to commercialize over the next 3 to 4 years. | We have a couple more, which are already there in the pipeline, so they would be executed also. | So could you help us understand how much of this reflects normalization of delayed customer procurement versus the structural gains such as the market… | So however, we do not see any change in the annual demand and that we have forecasted from our customers. | And if you can speak about the new pipeline, we were planning to launch working 8 to 10 products and planning to launch at least 1 or 2 products every… | I understand that there is this U.S. demand deferment as well that happened. | — |
| Guidance | We anticipate that commercial production at this new facility will commence by the first quarter of the next financial year. | Facility qualification activities are ongoing and we expect to commercialize this plant by last quarter of this financial year. | And second is given that we are still in line to achieve our EBITDA margin guidance, could you just throw some color on by which quarter we can expect… | Additionally, should we expect this growth trajectory to sustain through the rest of FY27? | So therefore, on an annualized basis, we expect to do better than our historical CAGR of 18% growth. | With that, as I've mentioned that in spite of the interunit sales, the growth in the API, we expect it to be in the double-digit growth in spite of th… | And that seems the full-year guidance will continue to be healthy if we add this back up. | In the coming few months, we expect to commercialize a couple of these APIs. |
| Margin | Yes, so my first question is that, could you just elaborate on the potential disruptors or risks that the management can identify as threats to our EB… | EBITDA for this quarter stood at INR 81.28 crores as compared to INR 72.15 crores in quarter 1 of the last year. | Secondly, on the EBITDA, if you could just give some idea? | The improvement in the gross margin reflects a strong pricing discipline, favorable product mix and limited competitive intensity across our key produ… | And in terms of margins, right, we have seen around 200 basis point kind of expansion in the gross margin. | And one final one, generally, before FY '24, at least, we had a heavy skew towards the second half in terms of our sales as well as EBITDA. | And if you see that excluding the injectables or excluding the Stellon, our EBITDA stands at 41%, which is pretty much in line with what you would hav… | Reported EBITDA margin for 9 months financial year '24 stood at 42.6% as compared to 36.9% for the same period last year which represents an increase … |
| People | And the last growth lever for us being the increased utilization of existing and new facilities by adding more customers, and products to be marketed … | And if you can provide utilization of the plants it would be helpful for the quarter? | Sir, firstly, can you provide the capacity utilization across all the facilities? | And also in the oral solid side, we have added the softgel facility and also continue to see capacity utilization for the new products that we have la… | If you can help us understand the update on the various plans and in terms of utilization as well, it would be great. | The second one is, what was the capacity utilization as of the second quarter across all the 3 sites? | And the final bookkeeping one, Lalitji, can you share the utilization rates for the three facilities, or maybe the injectable one as well? | Because during this five years, there are going to be different, milestones that will be achieved, whether it is, the utilization of Capacities or the… |
| Pricing | So it would be great, sir, if you could just share some insights on what key factors or strategies that have contributed to this consistency or maybe … | The one product you mentioned, apart from that, any offtake issue or any pricing issue in any of the API products? | Or is there any impact of pricing headwinds as well, right? | So based on the economies of scale, based on our expertise, we have a good grip on the pricing and that advantage, price benefit based on that, we hav… | Ankur, if you can talk about how the pricing trends were there in some of the top products, that would be really helpful. | So how are you seeing the pricing and all these things? | The next one is, can you comment on the pricing of your immunosuppressant portfolio in particular, especially in the context of these challenges aroun… | And would you like to share how the pricing has behaved for the top four, five products, especially in the API segment? |
| Revenue growth | This growth is in line with the overall growth of pharmaceutical drug consumption in the country. | With CDMO business, we will be able to generate large volumes which will accelerate the revenue growth and margin profile on the back of operating lev… | So given that the US already contributes 17% to the top line, before this, did we have front-end presence there? | Revenue for Q1 FY27 stood at INR257 crores compared to INR204 crores in the Q1 FY26, a growth of 26.2%. | So we have seen a big surge in this quarter in growth, 65% year-on-year in top line. | — | If you can just quantify if those challenges were not in place, how much revenue growth or how much revenue can be spilled over into subsequent quarte… | Our strategic plan involves introducing approximately 8 to 10 additional products over the next three years, especially in the field of oncology and a… |
What they said they would do
Sentences in which management set an expectation. Each names the speaker and the page of the transcript it came from.
| Date | Quarter | Who | What they said |
|---|---|---|---|
| 2024-08-20 | Q1FY25 | Biotecf for Mankind... | The split between our API and Formulation business was 79% and 21%, respectively, for Q1 FY '25, aligning with our long- term guidance of 80-20. |
| 2024-08-20 | Q1FY25 | Biotecf for Mankind... | Lastly, we are optimistic about the growth trajectory for both segments and remain committed to achieving our long-term CAGR guidance of revenue growth of 25% over a period of 5 years on the back of strong product pipeline of 8 to 10 products which would be commercialized in the next 3 to 4 years approvals from customers for our Limbasi facility with ample capacities to grow, commercialization of new injectable plant in this year facilitating growth from next year, increase in wallet share addition of new customers and geographies and CDMO opportunities accelerating the growth. |